Axsome Therapeutics Inc
AXSM
Market Cap$3.5B
Close$
$62.73
13.5% downside
Current Fair Value
13.5% downsideOvervalued by 13.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.50 Billion |
|---|---|
| Enterprise Value | $3.36 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-6.39 |
| Beta | 0.88 |
| Outstanding Shares | 47,495,827 |
| Avg 30 Day Volume | 626,086 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -11.81 |
|---|---|
| PEG | -2.32 |
| Price to Sales | 14.5 |
| Price to Book Ratio | 24.17 |
| Enterprise Value to Revenue | 13.37 |
| Enterprise Value to EBIT | -13.7 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 1.31 |
Revenue Sources
No data
ESG Score
No data
About Axsome Therapeutics Inc
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...